- Home
- CNNE vs PCRX Comparison
CNNE vs PCRX Comparison
Compare CNNE & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNNE
- PCRX
- Stock Information
- Founded
- CNNE 2014
- PCRX 2006
- Country
- CNNE United States
- PCRX United States
- Employees
- CNNE N/A
- PCRX N/A
- Industry
- CNNE Restaurants
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- CNNE Consumer Discretionary
- PCRX Health Care
- Exchange
- CNNE Nasdaq
- PCRX Nasdaq
- Market Cap
- CNNE 1.2B
- PCRX 1.2B
- IPO Year
- CNNE N/A
- PCRX 2011
- Fundamental
- Price
- CNNE $19.92
- PCRX $24.10
- Analyst Decision
- CNNE Buy
- PCRX Buy
- Analyst Count
- CNNE 2
- PCRX 9
- Target Price
- CNNE $22.00
- PCRX $29.89
- AVG Volume (30 Days)
- CNNE 942.2K
- PCRX 546.7K
- Earning Date
- CNNE 08-07-2025
- PCRX 07-29-2025
- Dividend Yield
- CNNE 2.41%
- PCRX N/A
- EPS Growth
- CNNE N/A
- PCRX N/A
- EPS
- CNNE N/A
- PCRX N/A
- Revenue
- CNNE $445,000,000.00
- PCRX $702,772,000.00
- Revenue This Year
- CNNE N/A
- PCRX $7.54
- Revenue Next Year
- CNNE $2.03
- PCRX $10.78
- P/E Ratio
- CNNE N/A
- PCRX N/A
- Revenue Growth
- CNNE N/A
- PCRX 3.08
- 52 Week Low
- CNNE $15.92
- PCRX $11.16
- 52 Week High
- CNNE $22.36
- PCRX $29.61
- Technical
- Relative Strength Index (RSI)
- CNNE 66.20
- PCRX 36.99
- Support Level
- CNNE $19.33
- PCRX $23.99
- Resistance Level
- CNNE $20.24
- PCRX $24.90
- Average True Range (ATR)
- CNNE 0.46
- PCRX 0.88
- MACD
- CNNE 0.03
- PCRX -0.21
- Stochastic Oscillator
- CNNE 81.08
- PCRX 11.61
About CNNE Cannae Holdings Inc.
Cannae Holdings Inc is a holding company that manages and operates a group of companies and investments. The company's reportable segments are Restaurant Group, Dun & Bradstreet, Alight, BKFC, Corporate and Other. Majority of the company's revenue is generated from its Restaurant Group segment which represents the operations of O'Charley's and Ninety Nine Restaurants.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.